According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.
Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases. In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the next-generation antibody therapeutics market. However, stringent regulatory requirements and long approval time for new drug restrains the growth of the market. Similarly, high costs of next-generation antibody therapeutics is a major concern for the market.
North America is the largest market for next-generation antibody therapeutics. This is mainly due to increasing prevalence of chronic diseases and increasing healthcare spending in the region. The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. On the basis of technology, biosimilar antibody products are the fastest growing segment. On the basis of therapeutic application, oncology is the largest segment in next-generation antibody therapeutics market.
Request Sample Report: http://www.persistencemarketresearch.com/samples/3713
Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics. Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
View Detail Report With TOC: http://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market.asp
The next-generation antibody therapeutics market is segmented as follows:
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies (BsAbs)
- Fc Engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
By Therapeutic Application
- Autoimmune/Inflammatory Diseases
For more Info: http://www.persistencemarketresearch.com/contact-us.asp
- North America
- Rest of the World (RoW)
Persistence Market Research PVT. LTD.
Persistence Market Research (PMR) is an innovative provider of market research reports and consulting services. The three PMR pillars of strength that have helped us win clients for years are: Quality Research, Quick Research, and In-depth Research.
PMR’s team of seasoned analysts and consultants are experts in their domain. At PMR, we process complex, exhaustive primary and secondary research data into valuable insight. We understand that each client has a unique problem statement, and address it with our strengths.